Shares of The Medicines Co. ( MDCO) sank 5.6% to $31.87 Tuesday after the company got a brokerage downgrade and set plans to sell 6 million shares.

"Our downgrade is based on valuation, as potential upside from current levels no longer supports a neutral rating," wrote UBS analyst Maged Shenouda, who lowered his rating to reduce from neutral.

Shares of Genesis Healthcare ( GHCI) soared 16.1% to $61.35 after the company said it's being acquired by private equity investment firms Formation Capital and JER Partners.

The firms will acquire the company for $63 a share in cash. Including the assumption of approximately $450 million of debt, the deal is worth $1.7 billion.

Shares of drugmaker Cephalon ( CEPH) rose Tuesday after JPMorgan upgraded the stock to overweight from neutral on strong sales trends.

"We believe CEPH shares deserve to trade at a premium," wrote JPMorgan health care analyst Adam Greene in a research report, saying the company's current valuation leaves room for upside. Shares rose 30 cents to $70.61.

Vertex Pharmaceuticals' ( VRTX) shares gained 1.4% to $38.32 on an upgrade to neutral from negative by Susquehanna Financial.

The stock slid late last year on disappointing data on its hepatitis C drug VX-950, and the company lost nearly $1 billion in market capitalization, but the side effects of the drug are now considered manageable and analyst Jason Kolbert says doctors should adopt the use of VX-950 quickly. Vertex is also expected to receive significant royalties from its partners Johnson & Johnson ( JNJ) and Mitsubishi.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective